Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ASNB OTCMKTS:MDIT NASDAQ:NURO OTCMKTS:RGIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNBEKIMAS$2.50-31.2%$3.73$0.55▼$1.75$14.50M0.373,162 shs3,996 shsMDITCytoCore$0.00$0.00▼$0.00N/A106.951 shsN/ANURONeuroMetrix$4.58$4.55$4.26▼$4.69$9.44M1.8210,370 shsN/ARGINRegenicin$0.00$0.00▼$0.75N/AN/AN/AN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNBEKIMAS-31.17%-33.33%-32.39%-38.05%-33.33%MDITCytoCore0.00%0.00%0.00%0.00%0.00%NURONeuroMetrix0.00%0.00%0.00%0.00%+0.66%RGINRegenicin0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNBEKIMAS$2.50-31.2%$3.73$0.55▼$1.75$14.50M0.373,162 shs3,996 shsMDITCytoCore$0.00$0.00▼$0.00N/A106.951 shsN/ANURONeuroMetrix$4.58$4.55$4.26▼$4.69$9.44M1.8210,370 shsN/ARGINRegenicin$0.00$0.00▼$0.75N/AN/AN/AN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNBEKIMAS-31.17%-33.33%-32.39%-38.05%-33.33%MDITCytoCore0.00%0.00%0.00%0.00%0.00%NURONeuroMetrix0.00%0.00%0.00%0.00%+0.66%RGINRegenicin0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNBEKIMAS 0.00N/AN/AN/AMDITCytoCore 0.00N/AN/AN/ANURONeuroMetrix 0.00N/AN/AN/ARGINRegenicin 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNBEKIMASN/AN/AN/AN/A$0.03 per shareN/AMDITCytoCoreN/AN/AN/AN/AN/AN/ANURONeuroMetrix$3.03M3.11N/AN/A$13.18 per share0.35RGINRegenicinN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNBEKIMAS-$290K-$1.05N/AN/AN/AN/A-7,902.31%-5,274.01%N/AMDITCytoCoreN/AN/AN/AN/AN/AN/AN/AN/AN/ANURONeuroMetrix-$6.53M-$4.59N/AN/AN/A-203.71%-42.56%-39.26%N/ARGINRegenicinN/AN/AN/AN/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNBEKIMASN/AN/AN/AN/AN/AMDITCytoCoreN/AN/AN/AN/AN/ANURONeuroMetrixN/AN/AN/AN/AN/ARGINRegenicinN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNBEKIMASN/A0.120.12MDITCytoCoreN/AN/AN/ANURONeuroMetrixN/A13.8812.70RGINRegenicinN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNBEKIMASN/AMDITCytoCoreN/ANURONeuroMetrix19.40%RGINRegenicin0.01%Insider OwnershipCompanyInsider OwnershipASNBEKIMAS7.80%MDITCytoCore85.40%NURONeuroMetrix7.30%RGINRegenicinN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNBEKIMAS115.80 million5.35 millionNot OptionableMDITCytoCore71N/AN/ANot OptionableNURONeuroMetrix202.06 million1.90 millionNot OptionableRGINRegenicin3165.77 millionN/ANot OptionableRGIN, ASNB, MDIT, and NURO HeadlinesRecent News About These CompaniesMade Scientific, Regenicin announce manufacturing relationship to advance NovaDerm toward US FDA product approvalApril 27, 2026 | pharmabiz.comPMade Scientific and Regenicin Announce Manufacturing Relationship to Advance NovaDerm Toward FDA Product ApprovalApril 23, 2026 | marketwatch.comHistoryOctober 20, 2024 | npr.orgNShaun Micallef's Origin OdysseyOctober 18, 2024 | sbs.com.auSRegenicin, Inc. (RGIN)September 5, 2024 | finance.yahoo.comThe Cambridge World History of SlaveryAugust 20, 2024 | cambridge.orgCThe Cambridge Ancient HistoryAugust 3, 2024 | cambridge.orgCHow to watch State of Origin overseas: International broadcasters, TV channels, live streams, timesJuly 19, 2024 | sportingnews.comSState of Origin: When and where is Origin in 2024?May 21, 2024 | sportingnews.comSLGBT+ History Month - Teaching ResourcesMay 3, 2024 | bbc.co.ukHistory & TraditionApril 20, 2024 | smith.eduSSevere cold front hits central, eastern regions; schools forced to delay start of new semesterFebruary 21, 2024 | globaltimes.cnGPalworld map – all locations, regions, and points of interestFebruary 2, 2024 | pcgamesn.comPAlexander boys fend off top challenger in Region 5January 30, 2024 | ajc.comAJohn Kerry praises Biden for preventing 'uncontrolled war in many regions'January 19, 2024 | foxnews.comJournal of the History of Economic ThoughtJanuary 7, 2024 | cambridge.orgCHistory of computers: A brief timelineDecember 24, 2023 | livescience.comLWATCH: Blue Origin successfully launches rocket in first flight since 2022 crashDecember 21, 2023 | wlwt.comWBlue Origin successfully completes rocket mission more than a year after failed launchDecember 21, 2023 | nydailynews.comBlue Origin launches New Shepard rocket, aces landing in 1st return to flight since 2022 failure (video)December 20, 2023 | space.comS Top HeadlinesView All HeadlinesIREN Is Flipping the Switch from Bitcoin to AIBy Jeffrey Neal Johnson | May 28, 2026As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingBy Jessica Mitacek | June 4, 2026Planet Labs: Coming Back Down to EarthBy Chris Markoch | June 8, 2026Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor TestBy Jessica Mitacek | June 6, 2026From Crypto to AI: Insiders Are Trading These 3 StocksBy Leo Miller | June 9, 2026RGIN, ASNB, MDIT, and NURO Company DescriptionsEKIMAS OTCMKTS:ASNB$2.50 -1.13 (-31.17%) As of 06/18/2026EKIMAS Corp. engages in the development of polymer materials, which provide characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. The firm's products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Las Vegas, NV.CytoCore OTCMKTS:MDITMedite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.NeuroMetrix NASDAQ:NURONeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.Regenicin OTCMKTS:RGINRegenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
